For every treatment team and researcher to have instant access to expert opinions and the latest evidence-based information in AML, to aid in treatment decisions and improve the lives of patients globally.
Enhance the collective knowledge base in AML through global multichannel dissemination of the most up-to-date evidence-based information on AML, to help inform on disease management and treatment strategies.
The AML Hub was founded in partnership with the European LeukemiaNet (ELN) in 2016. The ELN is a publicly-funded network of excellence, where clinicians and scientists improve therapy options for patients with leukemia worldwide. Together, they look to define strategies to improve leukemia characterization, its common diagnostic procedures and therapeutic standards, as well as to facilitate clinical and fundamental research. This approach results in the advancement of leukemia research and it supports equal access for all patients to the best possible care.
The AML Hub is brought to you by Scientific Education Support (SES). SES loves nothing more than building communities and networks to facilitate education through collaboration, ensuring that patients have access to the latest support and treatment options. The SES team takes care of the everyday management, content generation, and uploads onto the AML Hub, assisting the steering committees in keeping the site as up-to-date as possible.